Clinical Trials in Nashville

Showing 8421-8440 of 15,379 trials

A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS

NCT02633657

The primary objective is to assess the pharmacokinetics (PK) of gabapentin following the single-dose administration of HORIZANT (Gabapentin Enacarbil) in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe Primary Restless Legs Syndrome (RLS).

RLS

XenoPort, Inc.Started Jan 2016

Redwood City, California, United States • St Louis, Missouri, United States • Columbia, South Carolina, United States +1 more locations

COMPLETEDPhase 2< 1 mile

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

NCT02443155

This trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes mellitus.

DiabetesDiabetes Mellitus, Type 1

Novo Nordisk A/S308 participantsStarted Nov 2015

La Jolla, California, United States • Northridge, California, United States • Aurora, Colorado, United States +105 more locations

A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Find Trials by Condition in Nashville

Essure (Model ESS310) Placement Rate Study

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

A Phase II Study of M2951 in SLE

A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia

Peer Led Asthma Self Management for Adolescents: PLASMA

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

Rheos System for the Treatment of HFpEF Heart Failure

Wide Frequency Band Test of Hearing in Veterans

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

Bedside Optical Retinal Assessment of Hypoxic Ischemic Encephalopathy in Infants

Study of CAD-1883 for Spinocerebellar Ataxia

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer